Mikhail Eydelman - 05 Mar 2025 Form 4 Insider Report for Vaxcyte, Inc. (PCVX)

Reporting relationship: SVP, GEN COUNSEL & CORP SEC
Issuer ticker: PCVX
Reported as of: 05 Mar 2025
Net transaction value: -$246,649
SEC form: 4
Accepted by SEC: 07 Mar 2025, 16:43:03 UTC
Prior SEC filing: 03 Mar 2025
Source filing: View source filing
Reporting owner signature: Mikhail Eydelman, by /s/ Peter N. Efremenko, Attorney-In-Fact

Key filing fact

Mikhail Eydelman filed Form 4 for Vaxcyte, Inc. (PCVX) on 07 Mar 2025.

Key facts

This page summarizes Mikhail Eydelman's Form 4 filing for Vaxcyte, Inc. (PCVX).
5 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 07 Mar 2025, 16:43.

Change

Previous filing in this sequence was filed on 03 Mar 2025.
Current net transaction value: -$246,649.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PCVX transaction

Common Stock

Options Exercise

Transaction value: $107,050
Shares: +5,000
Change %: +12%
Price: $21.41
Shares after: 46,620
Date: 05 Mar 2025
Ownership: Direct

PCVX transaction

Common Stock

Sale

Transaction value: $184,487
Shares: -2,621
Change %: -5.6%
Price: $70.39
Shares after: 43,999
Date: 05 Mar 2025
Ownership: Direct
Footnotes: F1, F2

PCVX transaction

Common Stock

Sale

Transaction value: $161,107
Shares: -2,267
Change %: -5.2%
Price: $71.07
Shares after: 41,732
Date: 05 Mar 2025
Ownership: Direct
Footnotes: F1, F3

PCVX transaction

Common Stock

Sale

Transaction value: $8,105
Shares: -112
Change %: -0.27%
Price: $72.37
Shares after: 41,620
Date: 05 Mar 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PCVX transaction Derivative

Stock Option (right to buy)

Options Exercise

Transaction value: $0
Shares: -5,000
Change %: -3.3%
Price: $0.000000
Shares after: 144,497
Date: 05 Mar 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $21.41
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 4 footnotes

Footnote F1

The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on June 11, 2024.

Footnote F2

The price reported is a weighted-average price. The shares were sold at prices ranging from $69.745 to $70.735. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F3

The price reported is a weighted-average price. The shares were sold at prices ranging from $70.745 to $71.62. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.

Footnote F4

1/4 of the shares subject to the option vested on April 1, 2023, and 1/48 of the shares vest monthly thereafter, subject to Reporting Person's continuous service to the Company through each such date.